Stock Graphs and Charts
This is a complete list of financial data submitted by Halozyme Therapeutics, Inc. to the Securities and Exchange Commission (SEC) in their recent 10K and 10Q filings. These terms are taken from the XBRL portion of the filings.
Click on a term to see historical data and generate a time series chart from the historical filings.
Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)
APEN / Apollo Endosurgery Inc.
ARIA / ARIAD Pharmaceuticals, Inc.
AVIR / Aviragen Therapeutics, Inc.
AVXS / AveXis, Inc.
BOTA / Biota Pharmaceuticals, Inc.
CASI / CASI Pharmaceuticals, Inc.
CYTR / CytRx Corp.
EIGR / Eiger BioPharmaceuticals, Inc.
FENC / Fennec Pharmaceuticals Inc.
Related News Stories
Halozyme Therapeutics (HALO - Free Report) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items. (2-0)
Good day, ladies and gentlemen and welcome to the Halozyme Investor Call. We now have all of have speakers in conference. Please be aware that your line is in listen-only mode. At the conclusion on today’s presentation, we will open the floor for questions, [Operator Instructions]. (4-0)
Alexion Pharmaceuticals, Inc. (ALXN - Free Report) posted second-quarter 2018 adjusted earnings of $2.07 per share, which came in higher than the year-ago earnings of $1.56 by 32.7%. Earnings also beat the Zacks Consensus Estimate of $1.69. Strong product revenues drove the bottom line in the quarter. (1-0)
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. (4-3)
Good afternoon and welcome to the Halozyme Therapeutics First Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this call is being recorded. (52-0)